Published in Vaccine Weekly, December 23rd, 2009
several strains of influenza, including the swine flu strain
-- BiondVax's CEO Dr. Ron Babecoff: "This is an important indication
along the way towards the realization of the Company's vision of
ensuring protection against all flu strains with a single
Keywords: Biotechnology, Clinical Trial Research, Flu Vaccines, Immunization, Influenza Vaccines, Pharmaceuticals, Therapy, Treatment, Vaccination, BiondVax Pharmaceuticals Ltd.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly